PF-04457845 + Placebo

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Post-Traumatic Stress Disorder

Conditions

Post-Traumatic Stress Disorder

Trial Timeline

Oct 1, 2014 → Mar 1, 2015

NCT ID

NCT02216097

About PF-04457845 + Placebo

PF-04457845 + Placebo is a phase 2 stage product being developed by Pfizer for Post-Traumatic Stress Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT02216097. Target conditions include Post-Traumatic Stress Disorder.

What happened to similar drugs?

3 of 7 similar drugs in Post-Traumatic Stress Disorder were approved

Approved (3) Terminated (3) Active (1)

✅Galcanezumab-GnlmEli LillyApproved

✅AbobotulinumtoxinA + Normal salineIpsenApproved

✅Tramadol + PlaceboBrain BiotechApproved

🔄Quetiapine Fumarate + quetiapine fumarate placeboAstraZenecaPhase 3

❌Zoloft (Sertraline)PfizerPhase 3

❌Levetiracetam + PlaceboUCBPhase 3

❌Placebo + BrexpiprazoleLundbeckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02216097	Phase 2	Terminated	Oct 1, 2014	Mar 1, 2015	Post-Traumatic Stress Disorder

Competing Products

16 competing products in Post-Traumatic Stress Disorder

See all competitors

Product	Company	Stage	Hype Score
Galcanezumab-Gnlm	Eli Lilly	Approved	43
Quetiapine Fumarate + quetiapine fumarate placebo	AstraZeneca	Phase 3	40
Rizatriptan + Placebo	Merck	Pre-clinical	18
AMG 334	Novartis	Phase 2	35
Balovaptan + Placebo	Roche	Phase 2	35
Erenumab	Amgen	Phase 2	35
Zoloft (Sertraline)	Pfizer	Phase 3	32
Levetiracetam + Placebo	UCB	Phase 3	32
levetiracetam + Placebo + Levetriracetam	UCB	Phase 2/3	38
Placebo + Brexpiprazole	Lundbeck	Phase 3	29
Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching Placebo	Lundbeck	Phase 2	32
AbobotulinumtoxinA + Normal saline	Ipsen	Approved	40
Nabiximols + Placebo	Jazz Pharmaceuticals	Phase 2/3	27
60 mg PRAX-114 or 40 mg PRAX-114 + Placebo + 40 mg PRAX-114	Praxis Precision Medicines	Phase 2	24
MDMA	Nautilus Biotechnology	Phase 2	50
Tramadol + Placebo	Brain Biotech	Approved	33